Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Felix Lefort"'
Autor:
Romain Iaxx, Felix Lefort, Charlotte Domblides, Alain Ravaud, Jean-Christophe Bernhard, Marine Gross-Goupil
Publikováno v:
Therapeutics and Clinical Risk Management. 18:619-632
Cabozantinib is an oral tyrosine kinase inhibitor (TKI) with activity against several receptors involved in the angiogenesis pathway, including vascular endothelial growth factor receptor (VEGFR), c-MET and AXL. The antiangiogenic properties of caboz
Autor:
Charles Vauchier, Edouard Auclin, Philippe Barthélémy, Lucia Carril-Ajuria, Thomas Ryckewaert, Delphine Borchiellini, Zahra Castel-Ajgal, Mostefa Bennamoun, Luca Campedel, Antoine Thiery-Vuillemin, Elodie Coquan, Laurence Crouzet, Jean-François Berdah, Christine Chevreau, Raffaele Ratta, Aude Fléchon, Felix Lefort, Laurence Albiges, Marine Gross-Goupil, Yann-Alexandre Vano, Constance Thibault, Stéphane Oudard
Publikováno v:
Journal of oncology. 2022
Introduction. Immune checkpoint inhibitors (ICI) have been approved for front-line therapy in metastatic renal cell carcinoma (mRCC). However, progressive disease often occurs and subsequent therapies are needed. ICI rechallenge may be an option, but
Autor:
Pauline, Bertolaso, Véronique, Brouste, Anne-Laure, Cazeau, Henri, de Clermont-Gallerande, Franck, Bladou, Mathilde, Cabart, Felix, Lefort, Marine, Gross-Goupil
Publikováno v:
Clinical genitourinary cancer. 20(3)
Guidelines do not recommend FDG-PET CT for the staging of MIBC as a standard. The objectives of the study are to assess the accuracy of the FDG-PET CT for LN staging and to determine the rate of treatment modification according to FDG-PET CT results
Autor:
Pauline Bertolaso, Véronique Brouste, Anne-Laure Cazeau, Henri de Clermont-Gallerande, Franck Bladou, Mathilde Cabart, Felix Lefort, Marine Gross-Goupil
Publikováno v:
Clinical Genitourinary Cancer. 20:297-297.e6
Autor:
Ilfad Blazevic, Aude Flechon, Geraldine Pignot, Benoît Mesnard, Jerome Rigaud, Mathieu Roumiguié, Michel Soulie, Constance Thibault, Laurence Crouzet, Camille Goislard De Monsabert, Felix Lefort, Marine Gross-Goupil, Lucas Campedel, Mathieu Laramas, Elodie Martin, Leonor Chaltiel, Damien Pouessel
Publikováno v:
Journal of Clinical Oncology. 40:430-430
430 Background: Primary urethral cancer (PUC) is a rare and heterogeneous malignancy. Due to its scarcity, little data are available on the optimal treatment sequence and survival, especially in metastatic patients. Methods: Data from patients diagno
Autor:
Lucie Meynard, Derek Dinart, Aude Flechon, Carolina Saldana, Felix Lefort, Gwenaelle Gravis, Antoine Thiery-Vuillemin, Mathilde Cancel, Elodie Coquan, Sylvain Ladoire, Denis Maillet, Frederic Rolland, Elouen Boughalem, Sophie Martin, Mathieu Laramas, Laurence Crouzet, Baptiste Abbar, Sabrina Falkowski, Damien Pouessel, Guilhem Roubaud
Publikováno v:
Journal of Clinical Oncology. 40:492-492
492 Background: Immune checkpoints inhibitors (ICIs) have recently changed therapeutic landscape of la/mUC. Recent studies suggested an improvement of response to salvage chemotherapy (CT) after ICIs in several cancer types including urothelial carci
Autor:
Quentin, Durrechou, Charlotte, Domblides, Baptiste, Sionneau, Felix, Lefort, Amandine, Quivy, Alain, Ravaud, Marine, Gross-Goupil, Amaury, Daste
Publikováno v:
Cancer Management and Research
Immune checkpoint inhibitors (ICIs) have radically changed the clinical outcome of several cancers with durable responses. CTLA-4 (cytotoxic T lymphocyte antigen-4), PD-1 (programmed cell death protein 1) or PDL-1 (programmed cell death ligand protei
Autor:
Laurence Albiges, Bernard Escudier, Gwenaelle Gravis, Ronan Flippot, Alain Ravaud, Maxime Meylan, Nathalie Rioux-Leclercq, Marine Gross-Goupil, Gaëlle Fromont, Christophe Passot, Lionnel Geoffrois, Fréderic Rolland, Manon de Vries-Brilland, Jonathan Dauvé, Elena Spirina-Menand, Christine Chevreau, Ellen Blanc, Félix Lefort, Sylvie Negrier
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background Papillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC, and associated with poor outcomes in the metastatic setting. In this study, we aimed to comprehensively evaluate the immune tumor microenvironment (TME), largely
Externí odkaz:
https://doaj.org/article/e2ce2468aad14a5187730a92accb65ce
Autor:
Stergios Boussios, Giulia Baciarello, Felix Lefort, Elie El Rassy, Nicholas Pavlidis, Pauline Parent
Publikováno v:
Critical Reviews in Oncology/Hematology. 147:102882
Cancers of Unknown Primary Site (CUP) account for approximately 1-3 % of all malignant neoplasms. It represents a heterogeneous group of malignancies without a detectable primary and is characterized by aggressive clinical behavior. Patients with CUP
Autor:
Samuel Bitoun, Marie Kostine, Christophe Richez, Thomas Barnetche, Thierry Schaeverbeke, Gael Mouterde, Marie-Elise Truchetet, Maéva Zysman, Amaury Daste, Sorilla Prey, Alice Tison, Rémi Veillon, Caroline Dutriaux, Anne Pham-Ledard, Marie Beylot-Barry, Marine Gross-Goupil, Félix Lefort, Alexandra Ladouceur, Emilie Gerard, Charlotte Domblides, Baptiste Sionneau, Mathieu Larroquette
Publikováno v:
RMD Open, Vol 9, Iss 4 (2023)
Objective Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety
Externí odkaz:
https://doaj.org/article/dd729db8de80406ebd7112cf82a7704c